TRAIL produced from multiple myeloma cells is associated with osteolytic markers

Oncology Reports

Volumn 27, Issue 1, 2012, Pages 39-44

  Kawano, Yawara ^a   Ueno, Shikiko ^a   Masahiro, A B E ^b   Kikukawa, Yoshitaka ^a   Yuki, Hiromichi ^a   Iyama, Kenichi ^c   Okuno, Yutaka ^a   Mitsuya, Hiroaki ^a   Hata, Hiroyuki ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

^b UNIVERSITY OF TOKUSHIMA   (Japan)

^c KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Bone resorption; Multiple myeloma; TRAIL

Indexed keywords

DEOXYPYRIDINOLINE; DICKKOPF 1 PROTEIN; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; RNA; SYNDECAN 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ADULT; AGED; ARTICLE; BONE LESION; BONE MARROW; CALCIUM BLOOD LEVEL; CONTROLLED STUDY; CYTOPLASM; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; MYELOMA CELL; OSTEOLYSIS; PLASMACYTOMA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION;

ADULT; AGED; AGED, 80 AND OVER; AMINO ACIDS; CALCIUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MULTIPLE MYELOMA; OSTEOLYSIS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 84855275535     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2011.1491     Document Type: Article

References (25)

1. Lacey DL, Timms E, Tan HL, et al: Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93: 165-176, 1998. (Pubitemid 28180851)
2. Simonet WS, Lacey DL, Dunstan CR, et al: Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89: 309-319, 1997. (Pubitemid 27199902)
3. Emery JG, McDonnell P, Burke MB, et al: Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem 273: 14363-14367, 1998. (Pubitemid 28319153)
4. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A and Ashkenazi A: Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family. J Biol Chem 271: 12687-12690, 1996. (Pubitemid 26175834)
5. Vitovski S, Phillips JS, Sayers J and Croucher PI: Investigating the interaction between osteoprotegerin and receptor activator of NF-kappaB or tumor necrosis factor-related apoptosis-inducing ligand: evidence for a pivotal role for osteoprotegerin in regulating two distinct pathways. J Biol Chem 282: 31601-31609, 2007. (Pubitemid 350044899)
6. Colucci S, Brunetti G, Rizzi R, et al: T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. Blood 104: 3722-3730, 2004. (Pubitemid 39564450)
7. Yen ML, Tsai HF, Wu YY, Hwa HL, Lee BH and Hsu PN: TNF-related apoptosis-inducing ligand (TRAIL) induces osteoclast differentiation from monocyte/macrophage lineage precursor cells. Mol Immunol 45: 2205-2213, 2008.
8. Silvestris F, Cafforio P, Tucci M, Grinello D and Dammacco F: Upregulation of osteoblast apoptosis by malignant plasma cells: a role in myeloma bone disease. Br J Haematol 122: 39-52, 2003. (Pubitemid 36819337)
9. Tinhofer I, Biedermann R, Krismer M, Crazzolara R and Greil R: A role of TRAIL in killing osteoblasts by myeloma cells. FASEB J 20: 759-761, 2006. (Pubitemid 46671206)
10. Tian E, Zhan F, Walker R, et al: The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349: 2483-2494, 2003. (Pubitemid 38010074)
11. Abe M, Hiura K, Wilde J, et al: Role for macrophage inflammatory protein (MIP)-1alpha and MIP-1beta in the development of osteolytic lesions in multiple myeloma. Blood 100: 2195-2202, 2002. (Pubitemid 35001256)
12. Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M and Namba M: Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker, t(11;14)(q13;q32). Br J Haematol 73: 199-204, 1989. (Pubitemid 19256112)
13. Ikeyama S, Nakagawa S, Arakawa M, Sugino H and Kakinuma A: Purification and characterization of IgE produced by human myeloma cell line, U266. Mol Immunol 23: 159-167, 1986. (Pubitemid 16188335)
14. Matsuoka Y, Moore GE, Yagi Y and Pressman D: Production of free light chains of immunoglobulin by a hematopoietic cell line derived from a patient with multiple myeloma. Proc Soc Exp Biol Med 125: 1246-1250, 1967.
15. Uneda S, Hata H, Matsuno F, et al: Macrophage inflammatory protein-1 alpha is produced by human multiple myeloma (MM) cells and its expression correlates with bone lesions in patients with MM. Br J Haematol 120: 53-55, 2003. (Pubitemid 36056908)
16. Herrnring C, Reimer T, Jeschke U, et al: Expression of the apoptosis-inducing ligands FasL and TRAIL in malignant and benign human breast tumors. Histochem Cell Biol 113: 189-194, 2000. (Pubitemid 30196530)
17. Tatetsu H, Ueno S, Hata H, et al: Down-regulation of PU.1 by methylation of distal regulatory elements and the promoter is required for myeloma cell growth. Cancer Res 67: 5328-5336, 2007. (Pubitemid 46997272)
18. Carlson K, Larsson A, Simonsson B, Turesson I, Westin J and Ljunghall S: Evaluation of bone disease in multiple myeloma: a comparison between the resorption markers urinary deoxypyridinoline/creatinine (DPD) and serum ICTP, and an evaluation of the DPD/osteocalcin and ICTP/osteocalcin ratios. Eur J Haematol 62: 300-306, 1999. (Pubitemid 29232256)
19. Silvestris F, Cafforio P, Tucci M and Dammacco F: Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma. Blood 99: 1305-1313, 2002. (Pubitemid 34547085)
20. Jourdan M, Reme T, Goldschmidt H, et al: Gene expression of anti- and pro-apoptotic proteins in malignant and normal plasma cells. Br J Haematol 145: 45-58, 2009.
21. Zhan F, Huang Y, Colla S, et al: The molecular classification of multiple myeloma. Blood 108: 2020-2028, 2006. (Pubitemid 44395016)
22. Broyl A, Hose D, Lokhorst H, et al: Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 116: 2543-2553, 2010.
23. Corallini F, Celeghini C, Rimondi E, et al: TRAIL down-regulates the release of osteoprotegerin (OPG) by primary stromal cells. J Cell Physiol 226: 2279-2286, 2011.
24. Wiley SR, Schooley K, Smolak PJ, et al: Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3: 673-682, 1995. (Pubitemid 26091143)
25. Perez LE, Parquet N, Shain K, et al: Bone marrow stroma confers resistance to Apo2 ligand/TRAIL in multiple myeloma in part by regulating c-FLIP. J Immunol 180: 1545-1555, 2008.